Abstract: Provided is a multilateral junction, a well system, and a method. The multilateral junction, in one aspect, includes a lateral branch template having a lateral window for positioning proximate a junction between a lateral wellbore and a main wellbore, and a lateral branch connector adapted to be sealably engaged to the lateral branch template, a portion of the lateral branch connector extending through the lateral window. The multilateral junction, according to this aspect, further includes one or more sealing elements configured to expand in volume located proximate a joint between the lateral branch template and the lateral branch connector.

Abstract: Apparatus and methods for transmitting an electrical signal in a wellbore. A tool comprising a wire mesh is introduced into a wellbore. The wire mesh is disposed along at least a portion of the axial length of the tool. An electrical signal is transmitted along the wire mesh to or from a wellbore device disposed in the wellbore.

Abstract: Apparatus and methods for transmitting an electrical signal in a wellbore. A tool comprising a wire mesh is introduced into a wellbore. The wire mesh is disposed along at least a portion of the axial length of the tool. An electrical signal is transmitted along the wire mesh to or from a wellbore device disposed in the wellbore.

Abstract: Embodiments of the instant disclosure relate to novel compositions and methods for treating cancer in a subject. In certain embodiments, long noncoding RNAs (lncRNAs) are modified to reduce or eliminate methylation at target nucleotides within the lncRNAs to modulate activities such as tumor promoting activities. In some embodiments, the lncRNAs includes HOTAIR (HOX (homeobox) transcript antisense intergenic RNA) or fragment thereof, where one or more nucleotides are substituted to reduce or eliminate methylation at the one or more nucleotide positions. In certain embodiments, the HOTAIR methylation site includes, but is not limited to, a modification at adenine 783 (A783) of SEQ ID. NO:1 or fragment thereof or equivalent position thereof. In other embodiments, modified lncRNAs disclosed herein can be used to treat a health condition where naturally-occurring lncRNAs have adverse effects. In some embodiments, a composition including modified HOTAIR can be used to treat a subject with cancer.

Abstract: The present invention provides a means to modulate gene expression in vivo in a manner that avoids problems associated with CRISPR endogenous protein knock-out or knock-in strategies and strategies that provide for correction, or alteration, of single nucleotides. The invention includes inserting into the genome a nucleotide encoding a heterobifunctional compound targeting protein (dTAG) in-frame with the nucleotide sequence of a gene encoding an endogenously expressed protein of interest which, upon expression, produces an endogenous protein-dTAG hybrid protein. This allows for targeted protein degradation of the dTAG and the fused endogenous protein using a heterobifunctional compound.

Abstract: In a computer-implemented method for automatically presenting a visualization of information within a terminal for interfacing with a distributed version control system, an input is received at a command line interface of a terminal for interfacing with a distributed version control system, the input including an operation to be performed by the distributed version control system. The operation to be performed by the distributed version control system is identified based on the input. The operation is executed to generate output of the operation. The output is displayed within the command line interface. A graphical visualization of the output is automatically displayed within a visualization pane of the terminal, wherein the graphical visualization is interactive.

Abstract: In a computer-implemented method for automatically presenting a visualization of information within a terminal for interfacing with a distributed version control system, an input is received at a command line interface of a terminal for interfacing with a distributed version control system, the input including an operation to be performed by the distributed version control system. The operation to be performed by the distributed version control system is identified based on the input. The operation is executed to generate output of the operation. The output is displayed within the command line interface. A graphical visualization of the output is automatically displayed within a visualization pane of the terminal, wherein the graphical visualization is interactive.

Abstract: The present invention provides a means to modulate gene expression in vivo in a manner that avoids problems associated with CRISPR endogenous protein knock-out or knock-in strategies and strategies that provide for correction, or alteration, of single nucleotides. The invention includes inserting into the genome a nucleotide encoding a heterobifunctional compound targeting protein (dTAG) in-frame with the nucleotide sequence of a gene encoding an endogenously expressed protein of interest which, upon expression, produces an endogenous protein-dTAG hybrid protein. This allows for targeted protein degradation of the dTAG and the fused endogenous protein using a heterobifunctional compound.

Abstract: This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.

Abstract: The present invention provides a means to modulate gene expression in vivo in a manner that avoids problems associated with CRISPR endogenous protein knock-out or knock-in strategies and strategies that provide for correction, or alteration, of single nucleotides. The invention includes inserting into the genome a nucleotide encoding a heterobifunctional compound targeting protein (dTAG) in-frame with the nucleotide sequence of a gene encoding an endogenously expressed protein of interest which, upon expression, produces an endogenous protein-dTAG hybrid protein. This allows for targeted protein degradation of the dTAG and the fused endogenous protein using a heterobifunctional compound.

Abstract: A liner (10) for lining a microwave oven (M) to prevent food from adhering to the top (T), sides (R, L), and floor (F) of the microwave during the cooking of food. The liner has a top panel (12), and three side panels (18, 20, 22) which are initially folded in place with the top panel of the liner first being installed and then the other panels in a prescribed sequence. A two-sided tape (14) is used for adhering the panels to corresponding sides of the microwave. The liner further includes a panel (28) similarly installed on the floor of the microwave, this piece having a central opening which exposes the turntable installed in the floor of the microwave. A separate circularly shaped panel (30) attaches to the top of the turntable.

Abstract: This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.

Abstract: This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.

Abstract: The present invention provides a means to modulate gene expression in vivo in a manner that avoids problems associated with CRISPR endogenous protein knock-out or knock-in strategies and strategies that provide for correction, or alteration, of single nucleotides. The invention includes inserting into the genome a nucleotide encoding a heterobifunctional compound targeting protein (dTAG) in-frame with the nucleotide sequence of a gene encoding an endogenously expressed protein of interest which, upon expression, produces an endogenous protein-dTAG hybrid protein. This allows for targeted protein degradation of the dTAG and the fused endogenous protein using a heterobifunctional compound.

Abstract: This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.

Abstract: A liner (10) for lining a microwave oven (M) to prevent food from adhering to the top (T), sides (R, L), and floor (F) of the microwave during the cooking of food. The liner has a top panel (12), and three side panels (18, 20, 22) which are initially folded in place with the top panel of the liner first being installed and then the other panels in a prescribed sequence. A two-sided tape (14) is used for adhering the panels to corresponding sides of the microwave. The liner further includes a panel (28) similarly installed on the floor of the microwave, this piece having a central opening which exposes the turntable installed in the floor of the microwave. A separate circularly shaped panel (30) attaches to the top of the turntable.

Abstract: The present invention provides a means to modulate gene expression in vivo in a manner that avoids problems associated with CRISPR endogenous protein knock-out or knock-in strategies and strategies that provide for correction, or alteration, of single nucleotides. The invention includes inserting into the genome a nucleotide encoding a heterobifunctional compound targeting protein (dTAG) in-frame with the nucleotide sequence of a gene encoding an endogenously expressed protein of interest which, upon expression, produces an endogenous protein-dTAG hybrid protein. This allows for targeted protein degradation of the dTAG and the fused endogenous protein using a heterobifunctional compound.

Abstract: This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.

Abstract: A vehicle barrier apparatus includes a vertical barrier component connected to a stabilizer beam and capable of selective deployment by a rapid deployment assembly. One end of the stabilizer beam is rotatably connected to the vertical barrier component. Movement of a locking block in the stabilizer beam using a locking handle connected to a locking shaft allows a tensioning cable and tensioning spring assembly to raise the vertical barrier component. Straps extending around both the vertical barrier component and the stabilizer beam prevent over-extension and provide additional resistance to vehicle impact. The locking handles and shafts of multiple vehicle barrier apparatuses may be connected in series, allowing a user to actuate a single locking handle to simultaneously deploy multiple vertical barrier components.